Quantcast

Latest MiMedx Group Inc. Stories

2014-09-08 16:25:56

MARIETTA, Ga., Sept. 8, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will be hosting and webcasting its Analyst Day on Tuesday, October 14, 2014, in New York, New York. Parker H. "Pete" Petit, Chairman and CEO; William C. Taylor, President and COO; Michael J. Senken, Chief Financial Officer; and...

2014-09-03 12:24:59

Study determines allografts with both amnion and chorion contain approximately 20 times more cytokines than the competitive single layer amnion allografts evaluated MARIETTA, Ga., Sept. 3, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed scientific study in the scientific...

2014-08-04 16:25:55

MARIETTA, Ga., Aug. 4, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 34(th) Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are...

2014-07-29 00:21:13

In the news release, MiMedx Announces Record Second Quarter Results, issued 28-Jul-2014 by MiMedx Group, Inc. over PR Newswire, we are advised by the company that under the "Highlights include section," the fourth bulletpoint should read "Company issues third quarter revenue guidance of $30-$32 million with Operating Profit" rather than "Company issues third quarter revenue guidance of $30-$31 million with Operating Profit" as originally issued inadvertently. Additional stylistic changes...

2014-07-28 16:26:58

Revenue Increases by 89% Over 2013 Second Quarter MARIETTA, Ga., July 28, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2014. Highlights include: -- Revenue exceeds upper end of guidance and increases by 89% over Q2 2013 to $25.6 million --...

2014-07-23 08:30:59

MARIETTA, Ga., July 23, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has filed its initial Investigational New Drug ("IND") application with the Food and Drug Administration ("FDA"). The IND submission, which was filed yesterday, July 22, 2014, is the Company's initial submission for certain indications...

2014-07-22 16:27:39

EpiFix® shown to have most rapid and complete wound healing, least wastage and lowest cost per patient among three advanced wound care products in retrospective analysis of data. MARIETTA, Ga., July 22, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced for investors today that a peer-reviewed study, "An Evaluation of...

2014-07-15 08:29:13

MARIETTA, Ga., July 15, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the second quarter, ended June 30, 2014, will be released before the opening of the market on Tuesday, July 29, 2014. MiMedx will host a live broadcast of its second quarter conference call on Tuesday, July 29, 2014, at...

2014-07-14 12:27:09

MARIETTA, Ga., July 14, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Medicare Administrative Contractor responsible for Jurisdiction H, which has approximately five million beneficiaries in Texas, Oklahoma, Louisiana, New Mexico, Colorado, Mississippi and Arkansas, has revised its Local Coverage...

2014-06-04 12:29:13

MARIETTA, Ga., June 4, 2014 /PRNewswire/ -- The Board of Directors of MiMedx Group, Inc. (NASDAQ: MDXG), announced today that the Board applauds the dismissal of the lawsuit brought by the Securities and Exchange Commission ("SEC") against the Company's Chairman and CEO, Parker H. "Pete" Petit. The SEC had brought a civil action against Mr. Petit alleging that in 2007, when he was Chairman and CEO of Matria Healthcare, Inc. (NASDAQ: MATR), he provided inside information to a friend...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related